Evidence map›Paper›PMID 25415291›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2015

Time to initiation of antiretroviral therapy among patients who Are ART eligible in Rwanda: improvement over time.

Chloe A Teasdale, Chunhui Wang, Uwinkindi Francois, Jean dʼAmour Ndahimana, Mutabazi Vincent, Ruben Sahabo, Wafaa M El-Sadr, Elaine J Abrams, Identifying Optimal Models for HIV Care in Africa Study

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Chloe A Teasdale*ICAP-Columbia University, New York, NY; †Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; and ‡Rwanda Biomedical Center, Kigali, Rwanda.
Chunhui Wang
Uwinkindi Francois
Jean dʼAmour Ndahimana
Mutabazi Vincent
Ruben Sahabo
Wafaa M El-Sadr
Elaine J Abrams
Identifying Optimal Models for HIV Care in Africa Study
Columbia University · USRwanda Biomedical Center · RW

Funding

RAPID EXP. OF ART FOR HIV-INFECTED PERSONS IN SELECTED COUNTRIES FOR PEPFARU62PS223540 · PS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EL-SADR, WAFAA M. · 2004 to 2011
$554.7M
TECHNICAL ASSISTANCE IN SUPPORT OF HIV PREVENTION, CARE AND TREATMENT PROGRAMSU2GPS001537 · PS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI JUSTMAN, JESSICA · 2009 to 2014
$13.6M
NCHHSTP CDC HHS 5U62PS223540NCHHSTP CDC HHS U2G PS001537NCHHSTP CDC HHS U62 PS223540PEPFARPHS HHS 5U2GPS001537
6 · The paper itself

Abstract

backgroundDelayed initiation of antiretroviral therapy (ART) in eligible patients is a concern in resource-limited countries.

methodsWe analyzed data on HIV-positive patients ≥15 years enrolled at 41 ICAP-supported health care facilities in Rwanda, 2005-2010, to determine time to ART initiation among patients eligible at enrollment compared with those ineligible or of indeterminate eligibility who become eligible during follow-up. ART eligibility was based on CD4 cell count (CD4) and WHO staging; patients lacking CD4 and WHO stage were considered indeterminate. Cumulative incidence of reaching ART eligibility and to ART initiation after eligibility was generated using competing risk estimators.

resultsA total of 31,033 ART-naive adults were enrolled; 64.2% were female. At enrollment, 10,158 (32.7%) patients were ART eligible, 13,372 (43.1%) were ineligible for ART, and 7503 (24.2%) patients were indeterminate. Among patients retained in care pre-ART eligibility, 17.9% [95% confidence interval (CI): 17.2 to 18.6] of ineligible and 22.8% (95% CI: 21.7 to 23.8) of indeterminate patients at enrollment reached ART eligibility within 12 months. Cumulative incidence of ART initiation within 3 months for patients eligible at enrollment was 77.2% (95% CI: 76.4 to 78.0) compared with 67.9% (95% CI: 66.4 to 69.3) for ineligible and 63.8% (95% CI: 61.9 to 65.8) for patients with indeterminate eligibility at enrollment (P < 0.05). Over the study period, there was more rapid ART initiation for patients who became ART eligible.

conclusionsWe found higher rates of ART initiation within 3 months among patients who were ART eligible at enrollment compared with those who reached eligibility during follow-up. From 2006 to 2011, earlier initiation of ART after eligibility was observed likely reflecting improved program quality.

Indexed as

AdolescentAdultAgedAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountFemaleHIV InfectionsHumansLongitudinal StudiesMaleMiddle AgedRwandaSeverity of Illness IndexTime FactorsYoung AdultAnti-Retroviral Agents

Identifiers

PMID25415291
PMCPMC5074335
OpenAlexW2072163976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.